The PCOS to PMOS name change - now what about diagnosis and treatment?

The PCOS to PMOS name change does not rewrite diagnostic criteria overnight, but it is designed to shift how the condition is evaluated, treated, and researched over the next three to five years. In practical terms, the new name is expected to prompt earlier metabolic screening, broader specialist involvement, better insurance coverage for non-reproductive interventions, and a clinical conversation that encompasses the full scope of a multisystem condition rather than focusing almost exclusively on fertility. For women living with this condition, these shifts matter.

What stays the same: diagnostic criteria

The core diagnostic criteria for PMOS are the same ones used to diagnose PCOS. Providers will continue to look for: irregular or absent ovulation, signs of excess androgens such as acne, excess facial or body hair, or hair thinning, and relevant ultrasound findings where appropriate. A formal diagnosis still requires at least two of these features to be present.

According to Prism News, the diagnosis itself does not change with the new name. What changes is the clinical framing and, over time, the guidelines that govern what happens after that diagnosis is made.

During the three-year transition period, both PCOS and PMOS will appear in clinical and research settings. Disease classification systems in 195 countries will be updated, medical education curricula will be revised, and clinical guidelines will transition to the new terminology. Your current diagnosis remains valid. If your provider still uses the term PCOS, that is expected during this period.

What changes: the metabolic lens

The most significant practical shift the name is designed to create is the routine addition of metabolic screening to the diagnostic and ongoing care process. Under the PCOS framework, metabolic evaluation was often secondary, something that happened if a woman developed overt symptoms of metabolic dysfunction rather than as standard practice from the point of diagnosis.

The new name, by centering metabolic function in the condition's identity, creates a stronger clinical mandate for metabolic assessment from the start. The American Journal of Managed Care reports that the therapeutic framing shifts toward targeting upstream metabolic and neuroendocrine drivers, such as insulin resistance, alongside reproductive goals. That is a meaningful change for women who have been managed primarily with oral contraceptives and told to return when they want to conceive.

"Women are armed with a ton of information. They just may not know how does this apply to me?"

— Jessica Nazzaro, DO, FACOG, NCMP, Board-Certified OB-GYN and National Certified Menopause Practitioner

Expanded specialist involvement

Because PMOS is now formally named as a polyendocrine and metabolic condition, the expectation is that endocrinologists, metabolic specialists, and cardiologists will become more routinely involved in the care of women with the condition, not just gynecologists and reproductive endocrinologists.

As Dr. Christina Boots, associate professor of obstetrics and gynecology at Northwestern's Feinberg School of Medicine, noted in CNN's coverage of the name change, because PMOS impacts so many parts of the body, all kinds of medical specialties should be more aware and collaborate to effectively treat patients. That collaborative, multidisciplinary care model has been the exception rather than the rule for women with PCOS. The name change is designed to make it more standard.

For women who have felt that their condition was being managed in silos, with one provider for their cycles and another for their skin and no one connecting the dots, the PMOS framing explicitly names the whole-body nature of the condition in a way that makes multidisciplinary care the logical clinical response.

Research funding and treatment development

Naming a condition accurately shapes what questions get asked and funded. When PCOS was framed as a reproductive condition, research funding and treatment development followed accordingly, with fertility outcomes as the primary endpoint. The metabolic, cardiovascular, and psychological dimensions of the condition were underfunded relative to their actual impact on women's health.

The PMOS name change is expected to shift that balance. As Dr. Christina Boots also noted, recognizing that PMOS spans reproductive, mental, and metabolic health may help enhance the number of research dollars and the number of studies directed toward understanding and treating it comprehensively. Women's health has been notoriously underfunded, and more accurate naming of the conditions that affect women is one lever for changing that.

"There's just not much research done because we've never been a population that was important enough to have the research for."

— Dominique Landry, Founder of Fit Enough

Insurance and access implications

Disease classification systems determine what interventions are covered under insurance. When a condition is classified primarily as a reproductive disorder, metabolic interventions, including dietary counseling, insulin-sensitizing therapies, and cardiovascular monitoring, may not be covered as standard care. A classification that includes metabolic dysfunction as a core feature creates a stronger case for covering those interventions.

The transition roadmap published alongside the Lancet consensus paper includes updates to international disease classification systems in 195 countries, according to Contemporary OB/GYN. As those updates take effect, women with PMOS may find broader coverage for the full spectrum of care the condition requires.

How to advocate for updated care right now

The clinical and insurance systems will take time to fully transition. In the meantime, women can advocate for more comprehensive care within existing frameworks. The most effective approach is arriving at appointments with a complete picture of symptoms across all systems, not just reproductive ones, and explicitly asking about metabolic evaluation.

Specific questions worth raising with your provider include: Can we assess my fasting insulin and HOMA-IR? Has my cardiovascular risk been evaluated? Are there metabolic dimensions of my condition that we have not yet addressed? Do my current symptoms warrant a referral to an endocrinologist?

Dr. Tosin Odunsi, MD, MPH, FACOG advises: "Coming prepared with questions can really help. What are the two or three that are most important? Because we can't do 15 questions." Picking the two or three metabolic questions that are most relevant to your current symptoms is a practical way to move the conversation forward in a limited appointment window.

For more on what the name change means at a foundational level, see our guide on what PMOS is and why PCOS just got renamed. For the science behind the metabolic dimension, see what PMOS and insulin resistance have to do with each other. And for what the name change means for the future of women's health research and policy, see our guide on the research and policy implications of PMOS.

Frequently asked questions

Do I need to get a new diagnosis now that PCOS has been renamed PMOS?

No. Your existing PCOS diagnosis remains valid. The name change does not require you to be rediagnosed. Over time, medical records and classification systems will be updated to use the PMOS terminology, but a diagnosis you already have carries the same clinical meaning under the new name.

Will my treatment change because of the name change?

Not immediately. Current treatment protocols remain in place during the transition period. What the name change is designed to do over time is expand the scope of care to include routine metabolic assessment and management alongside reproductive interventions. If you feel your current care does not address the metabolic dimensions of your condition, you can raise this directly with your provider now, without waiting for guidelines to update.

What metabolic tests should I ask my provider about?

Fasting glucose, fasting insulin, HOMA-IR, a fasting lipid panel, and blood pressure assessment are the core metabolic markers relevant to PMOS. These can be ordered alongside standard hormonal workup by most primary care providers and gynecologists, even before formal PMOS guidelines are updated.

Will the name change improve insurance coverage for PMOS treatment?

Over time, updates to international disease classification systems that include metabolic dysfunction as a core feature of PMOS are expected to strengthen the case for insurance coverage of metabolic interventions. This will take time to implement across different healthcare systems and countries. In the interim, documenting the metabolic features of your condition in clinical records can support coverage arguments.

Should I be seeing an endocrinologist as well as a gynecologist for PMOS?

For many women with PMOS, involvement of an endocrinologist who can assess and manage insulin resistance and broader hormonal function is clinically appropriate. Ask your primary care provider or gynecologist for a referral if metabolic screening has not been part of your care, or if your symptoms include significant energy dysregulation, weight changes, or signs of elevated androgen levels that have not been explained by reproductive management alone.

What is the timeline for the PMOS transition in clinical practice?

The transition roadmap published alongside the Lancet consensus paper covers a three-year period during which clinical guidelines, medical education curricula, disease classification systems, and patient resources will be updated across 195 countries. Full adoption will vary by region and specialty. The process is underway, but women should expect both terms to coexist in clinical settings for the next several years.

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting any new supplement, especially during pregnancy, breastfeeding, or while managing a medical condition. Keep out of reach of children.